Aaron Krabill

Dr. Aaron Krabill

Purdue University
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JKJatinder Kaur
Jatinder Kaur
XCXufeng Cao
Xufeng Cao
NANader S. Abutaleb
Nader S. Abutaleb
AEAhmed Elkashif
Ahmed Elkashif
AGAmanda L. Graboski
Amanda L. Graboski
DFDaniel P. Flaherty
Daniel P. Flaherty

25 March 2021 in ACS Infectious Diseases
Verified
Journal Article
Closed access
CHChad S. Hewitt
Chad S. Hewitt
NANader S. Abutaleb
Nader S. Abutaleb
AEAhmed E. M. Elhassanny
Ahmed E. M. Elhassanny
Alessio NocentiniAlessio Nocentini
Alessio Nocentini
XCXufeng Cao
Xufeng Cao
DFDaniel P. Flaherty
Daniel P. Flaherty

26 August 2019 in ChemBioChem
Verified
Journal Article
Closed access
PDF file
AKAaron Krabill
Aaron Krabill
HCHao Chen
Hao Chen
SHSajjad Hussain
Sajjad Hussain
CFChao Feng
Chao Feng
AAAmmara Abdullah
Ammara Abdullah
DFDaniel P. Flaherty
Daniel P. Flaherty

25 August 2021 in Biochemical Society Transactions
Verified
Journal Article
Closed access
PDF file
AKAaron Krabill
Aaron Krabill
ZZZhong-Yin Zhang
Zhong-Yin Zhang
Protein tyrosine phosphatases (PTPs) counteract the enzymatic activity of protein tyrosine kinases to modulate levels of both normal and disease-associated protein tyrosine phosphorylation. Aberrant activity of PTPs has been linked to the progression of many disease states, yet no PTP inhibitors are currently clinically available. PTPs are without a doubt a difficult drug target. Despite this, many selective, potent, and bioavailable PTP inhibitors have been described, suggesting PTPs should once again be looked at as viable therapeutic targets. Herein, we summarize recently discovered PTP inhibitors and their use in the functional interrogation of PTPs in disease states. In addition, an overview of the therapeutic targeting of PTPs is described using SHP2 as a representative target.

31 August 2020 in Biochemistry
Verified
Journal Article
Closed access
CHChad S. Hewitt
Chad S. Hewitt
AKAaron Krabill
Aaron Krabill
CDChittaranjan Das
Chittaranjan Das
DFDaniel P. Flaherty
Daniel P. Flaherty

25 February 2021 in Molecules
Verified
Journal Article
Open access
PDF file
AKAaron Krabill
Aaron Krabill
HCHao Chen
Hao Chen
SHSajjad Hussain
Sajjad Hussain
CHChad S. Hewitt
Chad S. Hewitt
RIRyan Dean Imhoff
Ryan Dean Imhoff
DFDaniel P. Flaherty
Daniel P. Flaherty
The deubiquitinating enzyme (DUB) UCHL1 is implicated in various disease states including neurodegenerative disease and cancer. However, there is a lack of quality probe molecules to gain a better understanding on UCHL1 biology. To this end a study was carried out to fully characterize and optimize the irreversible covalent UCHL1 inhibitor VAEFMK. Structure-activity relationship studies identified modifications to improve activity versus the target and a full cellular characterization was carried out for the first time with this scaffold. The studies produced a new inhibitor, 34, with an IC50 value of 7.7 µM against UCHL1 and no observable activity versus the closest related DUB UCHL3. The molecule was also capable of selectively inhibiting UCHL1 in cells and did not demonstrate any discernible off-target toxicity. Finally, the molecule was used for initial probe studies to assess the role of UCHL1 role in proliferation of myeloma cells and migration behavior in small cell lung cancer cells making 34 a new tool to be used in the biological evaluation of UCHL1.